Name: 글로벌 시장 동향
SKU: PH6732
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 혈관종 치료 시장은 2022년 2억 8,460만 달러 규모에 도달했으며, 2023년부터 2030년까지 연평균 3.8%의 성장률을 보이며 2030년에는 3억 8,100만 달러에 이를 것으로 예상됩니다.
영아 혈관종은 신생아의 약 4~5%에서 발생하는 가장 흔한 양성 혈관 종양입니다. 전 세계 혈관종 치료 시장은 최근 베타 차단제 치료법의 도입으로 인해 상당한 성장을 보였습니다. 예를 들어, 프로프라놀롤과 아테놀롤은 영아 혈관종 치료에 흔히 사용되는 베타 차단제입니다.
또한, 임상 시험 증가, 투자 증가, 연구 개발 확대와 같은 주요 성장 동력이 향후 시장 성장을 견인할 것으로 예상됩니다. 미국과 캐나다와 같은 국가에서 기술 발전이 크게 진전됨에 따라 북미 지역의 수요가 증가하고 있습니다. 아콘 파마슈티컬스, 화이자, 알마 레이저스, 앨러간 등 주요 기업들이 활발하게 시장에서 활동하고 있습니다.
시장 동향
시장 성장 동력
혈관종 치료 기술 발전
혈관종은 모세혈관의 수가 신생혈관 생성 과정을 통해 증가하는 양성 종양입니다. 주요 기업들의 기술 발전은 시장 성장을 견인하는 중요한 요소입니다. 이러한 효과적인 기술 발전은 연구 결과를 새로운 치료법으로 전환하고 수십억 명의 혈관종 환자들에게 더 나은 치료를 제공하는 데 기여하고 있습니다.
예를 들어, 2020년 9월 피에르 파브르 파마슈티컬스는 유아 혈관종의 조기 진단 및 의뢰를 위한 새로운 온라인 도구를 발표했습니다. 이 도구는 치료 지연으로 인한 합병증을 예방하는 데 도움이 될 수 있습니다. 본 연구는 유아 혈관종(IH)의 조기 진단, 의뢰 및 치료를 위한 유아 혈관종 의뢰 점수(IHReS)의 신뢰성과 사용 편의성을 강조합니다. 따라서 위의 요인들은 예측 기간 동안 시장 성장을 촉진하는 데 도움이 됩니다.
혈관종 치료 임상 시험 증가
전 세계적으로 혈관종에 대한 임상 시험이 증가함에 따라 혈관종 치료 시장의 수요가 증가하고 있습니다. 예를 들어, ClinicalTrial.gov에 따르면 2023년 5월 12일 인디애나 대학교는 천연 베리 추출물을 이용한 혈관종 치료에 대한 중재 연구를 진행했습니다. 이는 전향적, 무작위 배정, 이중 맹검, 위약 대조 병행군 연구입니다.
이 임상 시험의 목적은 6개월 치료 기간 동안 교정 재태 연령 4개월 미만의 영아의 혈관종 치료에 페디아베리(PediaBerry)의 사용을 평가하는 것입니다. 치료에는 페디아베리를 국소 투여용 크림 제형 또는 경구 투여용 물과 혼합하여 사용합니다.
시장 제약 요인
영아 혈관종 관련 합병증
영아 혈관종 합병증은 생명을 위협하는 합병증, 폐쇄성 합병증, 궤양성 합병증으로 분류됩니다. 생명을 위협하는 합병증으로는 기도 및 간 영아 혈관종이 있습니다. 중요한 구조물을 막거나 기능을 저해하는 기능적 합병증으로는 눈 주위, 코, 입술, 이하선, 귓바퀴 및 유방 영아 혈관종이 있습니다. 따라서 위와 같은 요인으로 인해 시장은 예측 기간 동안 성장이 저해될 것으로 예상됩니다.
세분화 분석
전 세계 혈관종 치료 시장은 유형, 진단, 치료, 최종 사용자 및 지역별로 세분화됩니다.
치료 부문 중 레이저 치료는 전 세계 혈관종 치료 시장 점유율의 약 38.5%를 차지했습니다.
전 세계적으로 혈관종에 대한 임상 시험이 증가함에 따라 혈관종 치료에 대한 수요가 증가하고 있습니다. 레이저 치료는 특정 파장의 빛을 사용하여 치유를 촉진하는 치료법으로, 주변 조직 손상을 최소화하면서 작은 부위에 집중적으로 시술할 수 있도록 합니다. 레이저 치료의 주요 목적은 염증과 근육통을 줄이는 것입니다.

예를 들어, clinicalTrials.gov에 따르면 2022년 8월 12일 매사추세츠 종합병원은 신생아 혈관종 성장에 대한 펄스 다이 레이저와 티몰롤 국소 용액, 그리고 경과 관찰을 비교하는 임상 시험을 진행했습니다. 이 연구의 목적은 펄스 다이 레이저 치료 또는 티몰롤 말레산염 0.5% 젤이 신생아 혈관종 치료에 도움이 되는지 알아보는 것이었습니다. 이처럼 위의 요인들은 시장 성장을 촉진하는 데 기여하고 있습니다.
지역별 시장 점유율
북미는 2022년 시장 점유율의 약 38.9%를 차지했습니다.
북미는 최근 몇 년간 혈관종 시장에서 상당한 비중을 차지해 왔으며, 의료비 지출 증가, 연구 개발 투자 확대, 혈관종 치료 기술 발전 등의 요인으로 인해 이러한 추세는 예측 기간 동안 지속될 것으로 예상됩니다.

예를 들어, 미국 국민건강보험지출계정(NHEA)에 따르면 미국의 연간 총 의료비 지출은 2.7% 증가한 4조 3천억 달러에 달했습니다. 의사 진료비는 연평균 3.5% 증가했으며, 병원 서비스(4.4%)와 임상 서비스(6.7%)는 더 높은 성장률을 보였습니다. 따라서 위의 요인들이 해당 지역의 성장을 촉진하는 데 기여했습니다.
경쟁 환경
시장의 주요 글로벌 기업으로는 Cutera Inc., Merck & Co., AbbVie Inc, Akorn Pharmaceuticals, Pfizer Inc., Alma Lasers Ltd., Allergan, Linline Medical Systems, Pierre Fabre, IRIDEX Corporation 등이 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 혈관종 치료 시장에 상당한 영향을 미쳤습니다. 팬데믹이 한창일 때 많은 의료 시스템이 과부하 상태에 빠졌고, 긴급하지 않은 의료 시술과 검진이 연기되거나 취소되었습니다. 이로 인해 혈관종 치료 연구가 지연되었습니다. 임상시험은 혈관종 치료 시장에서 새로운 치료법을 개발하고 치료 결과를 개선하는 데 필수적입니다.
그러나 팬데믹으로 인해 임상시험 진행에 차질이 생겼고, 많은 기관에서 환자 안전을 최우선으로 고려하여 등록을 일시적으로 중단하거나 프로토콜을 변경했습니다. 이로 인해 임상시험 완료 및 새로운 치료법의 출시가 지연되었습니다. 더욱이, 팬데믹 기간 동안 연구 개발 노력의 초점이 코로나19 백신 및 치료제 개발에 집중되면서 다른 분야로 옮겨갔습니다. 따라서 이러한 요인들로 인해 혈관종 치료 시장은 예측 기간 동안 다소 영향을 받을 것으로 예상됩니다.

유형별
• 모세혈관종
• 해면상 혈관종
• 복합 혈관종
• 소엽상 모세혈관종
진단 방법별
• 초음파
• MRI
• CT 스캔
• 기타
치료 방법별
• 약물 치료
• 레이저 치료
• 수술
• 베타 차단제
• 기타
최종 사용자별
• 병원
• 클리닉
• 진단 센터
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
• 2023년 6월, Candela Corporation은 Vbeam 계열 펄스형 염료 레이저(PDL) 제품군을 확장했다고 발표했습니다. • FDA는 소아 환자의 피부 모세혈관 기형(포도주색 반점, PWS) 및 영아 혈관종(IH) 또는 선천성 혈관종 치료에 595nm 파장의 사용을 승인했습니다.

• 2021년 12월, 보스턴의 센테너리 연구소와 하버드 의과대학이 주도한 연구에서 현재 베타 차단제 치료에 사용되는 화합물을 영아 혈관종 치료의 효율성과 안전성을 높이는 데 재활용할 수 있음을 보여주었습니다.

• 2023년 7월, 미국 레이저 의학 및 외과 학회(ASLMS)는 혈관성 모반 재단(VBF) 및 국제 다학제 팀과 협력하여 레이저 치료를 이용한 혈관성 모반 치료에 대한 통일된 가이드라인을 마련했습니다.

보고서 구매 이유:

• 유형, 진단, 치료, 최종 사용자 및 지역별 글로벌 혈관종 치료 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악하기 위함입니다. • 트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악합니다.

• 모든 세그먼트를 포함한 글로벌 혈관종 치료 시장의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 혈관종 치료 시장 보고서는 약 69개의 표, 70개의 그림, 195페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
Global Hemangioma Treatment Market reached US$ 284.6 million in 2022 and is expected to reach US$ 381.0 million by 2030 growing with a CAGR of 3.8% during the forecast period 2023-2030.
Infantile hemangioma is the most commonly occurring benign vascular tumor among infants affecting about 4% to 5% of newborns. The global hemangioma treatment market has witnessed significant growth in recent years due to the adoption of beta-blocker treatments. For instance, propranolol and atenolol are beta blockers that are commonly used as a treatment for infantile hemangiomas.
Furthermore, significant growth drivers such as increasing clinical trials, growing investments, and increasing research and developments give rise to future market growth. Due to the massive rise in technological advancements in countries like the U.S. and Canada, the market is experiencing a rise in demand from North American regions. Significant key players like Akorn Pharmaceuticals, Pfizer Inc., Alma Lasers Ltd., Allergan, and others are actively operating in the market.
Dynamics
Market Drivers
Rising Technological Advancements for Hemangioma Treatment
Hemangiomas are non-cancerous tumors where capillary blood vessels increase in number through the process of angiogenesis, and the major technological advancements from major companies help to drive market growth. These effective advancements help to transform research discoveries into new treatments and improve care for billions of people with hemangiomas.
For instance, in September 2020, Pierre Fabre Pharmaceuticals reported a new online tool for the early diagnosis and referral of infantile hemangioma that can help avoid complications stemming from delayed treatment. This study highlights the reliability and ease of use of the Infantile Hemangioma Referral Score (IHReS) for the early diagnosis, referral, and treatment of infantile hemangioma (IH). Thus, the above factors help to boost the market growth in the forecast period.
The Increasing Clinical Trials for Hemangioma Treatment
The rising clinical trials of hemangioma globally act as the driver to the growing demand for the hemangioma treatment market. For instance, according to ClinicalTrial.gov, on May 12, 2023, Indiana University conducted an interventional study on Natural Berry Extract Treatment of Hemangiomas. This is a prospective, randomized, double-blind, placebo-controlled parallel-group study.
The aim of this clinical trial is to evaluate the use of PediaBerry for the treatment of hemangiomas in infants less than 4 months of corrected gestation age over a 6-month treatment period. The treatment involves PediaBerry which will be mixed with a cream vehicle for topical administration or with water for oral administration.
Market Restraints
Complications Associated with Infantile Hemangiomas
Infantile hemangioma complications are classified as life-threatening, obstructive, and ulcerative. Life-threatening complications include airway and hepatic infantile hemangiomas. Functional complications obstructing vital structures or impairing function involve periocular, nasal, labial, parotid, auricular, and breast infantile hemangiomas. Thus, owing to the above factors the market is expected to hamper over the forecast period.
Segment Analysis
The global hemangioma treatment market is segmented based on type, diagnosis, treatment, end users, and region.
Laser Therapy from the Treatment Segment Accounted for Approximately 38.5% of the Global Hemangioma Treatment Market Share
The rising clinical trials of hemangiomas globally have contributed to the growing demand for hemangioma treatment. Laser therapy involves the use of specific wavelengths of light to stimulate healing by allowing surgeons to work at high levels of precision by focusing on a small area by damaging less of the surrounding tissue. The main aim of performing laser therapy is to reduce inflammation and muscle pains.
For instance, according to clinicalTrials.gov, on August 12, 2022, Massachusetts General Hospital conducted a clinical trial on pulsed-dye laser versus timolol topical solution versus observation on the growth of hemangioma in newborn. The purpose of this study is to find out if pulsed dye laser treatment or timolol maleate 0.5% gel can help infants who have a hemangioma. Thus, the above factors help to elevate the market growth.
Geographical Penetration
North America Accounted for Approximately 38.9% of the Market Share in 2022
North America has maintained a significant proportion of the hemangioma market in recent years, and this trend is anticipated to continue throughout the forecast period due to the factors such as an increase in healthcare expenditures, increasing research and developments, and technological advancementsin hemangioma treatment.
For instance, according to the National Health Expenditure Account (NHEA), the total annual healthcare expenditure in the United States is increased by 2.7% to $4.3 trillion. Physician spending grew by an average of 3.5% per year while hospital services (4.4%) and clinical services (6.7%) had higher growth rates. Thus, the above factors help to elevate the region's growth.
Competitive Landscape
The major global players in the market include Cutera Inc., Merck & Co., AbbVie Inc, Akorn Pharmaceuticals, Pfizer Inc., Alma Lasers Ltd., Allergan, Linline Medical Systems, Pierre Fabre, and IRIDEX Corporation among others.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the hemangioma treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in hemangioma treatment research. Clinical trials are vital for developing new treatments and improving outcomes in the hemangioma treatment market.
However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the hemangioma treatment market is expected to be moderately affected over the forecast period.
By Type
• Capillary Hemangioma
• Cavernous Hemangioma
• Compound Hemangioma
• Lobular Capillary Hemangioma
By Diagnosis
• Ultrasound
• MRI
• CT Scan
• Others
By Treatment
• Medical Therapy
• Laser Therapy
• Surgery
• Beta Blocker Medicines
• Others
By End Users
• Hospitals
• Clinics
• Diagnostic Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In June 2023, Candela Corporation announced that the Vbeam Family of Pulsed Dye Lasers (PDL) has expanded its FDA-cleared indications for use of the 595 nm wavelength to include the pediatric population for the treatment of cutaneous capillary malformations, also known as port wine stains (PWS), and infantile hemangiomas (IH) or congenital hemangiomas.
• In December 2021, research conducted led by the Centenary Institute and the Harvard Medical School, Boston, shows that a compound present in current beta blocker treatments could be repurposed to increase the efficiency and safety of infantile hemangioma therapies.
• In July 2023, the American Society for Laser Medicine and Surgery (ASLMS) worked with the Vascular Birthmarks Foundation (VBF) and an international, multidisciplinary team to create a consensus of uniform guidelines for treating vascular birthmarks with laser therapy.
Why Purchase the Report?
• To visualize the global hemangioma treatment market segmentation based on the type, diagnosis, treatment, end users, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global hemangioma treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global hemangioma treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Diagnosis
3.3. Snippet by Treatment
3.4. Snippet by End Users
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising technological advancements for hemangioma treatment
4.1.1.2. The increasing clinical trials for hemangioma
4.1.2. Restraints
4.1.2.1. Complications associated with infantile hemangiomas
4.1.3. Opportunity
4.1.3.1. Emerging markets of hemangioma treatments
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. By Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.1.2. Market Attractiveness Index, By Type
8.2. Capillary Hemangioma*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cavernous Hemangioma
8.4. Compound Hemangioma
8.5. Lobular Capillary Hemangioma
9. By Diagnosis
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
9.1.2. Market Attractiveness Index, By Diagnosis
9.2. Ultrasound*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. CT Scan
9.4. MRI
9.5. Others
10. By Treatment
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.1.2. Market Attractiveness Index, By Treatment
10.2. Medical Therapy
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Laser Therapy
10.4. Surgery
10.5. Beta Blocker Medicines
10.6. Others
11. By End Users
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
11.1.2. Market Attractiveness Index, By End Users
11.2. Hospitals*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Clinics
11.4. Diagnostic Centers
11.5. Others
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.2.7.1. U.S.
12.2.7.2. Canada
12.2.7.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.3.7.1. Germany
12.3.7.2. U.K.
12.3.7.3. France
12.3.7.4. Italy
12.3.7.5. Spain
12.3.7.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.4.8. Brazil
12.4.8.1. Argentina
12.4.8.2. Rest of South America
12.5. Asia Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.5.8. China
12.5.8.1. India
12.5.8.2. Japan
12.5.8.3. Australia
12.5.8.4. Rest of Asia Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies
14. Company Profiles
14.1. Cutera Inc.*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Merck & Co.
14.3. AbbVie Inc
14.4. Akorn Pharmaceuticals
14.5. Pfizer Inc.
14.6. Alma Lasers ltd.
14.7. Allergan
14.8. Linline Medical Systems
14.9. Pierre Fabre
14.10. IRIDEX Corporation
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

언급된 주요 기업들

Cutera Inc., 4.	Key Developments, Merck & Co., AbbVie Inc, Akorn Pharmaceuticals, Pfizer Inc., Alma Lasers ltd., Allergan, Linline Medical Systems, Pierre Fabre, IRIDEX Corporation

표 목록 (Tables)

List of Tables

Table 1 Global Hemangioma Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Hemangioma Treatment Market Value, By Diagnosis, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Hemangioma Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Hemangioma Treatment Market Value, By End Users, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Hemangioma Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Hemangioma Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 7 Global Hemangioma Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 8 Global Hemangioma Treatment Market Value, By Diagnosis, 2022, 2026 & 2030 (US$ Billion)

Table 9 Global Hemangioma Treatment Market Value, By Diagnosis, 2021-2030 (US$ Billion)

Table 10 Global Hemangioma Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Billion)

Table 11 Global Hemangioma Treatment Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 12 Global Hemangioma Treatment Market Value, By End Users, 2022, 2026 & 2030 (US$ Billion)

Table 13 Global Hemangioma Treatment Market Value, By End Users, 2021-2030 (US$ Billion)

Table 14 Global Hemangioma Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 15 Global Hemangioma Treatment Market Value, By Region, 2021-2030 (US$ Billion)

Table 16 North America Hemangioma Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 17 North America Hemangioma Treatment Market Value, By Diagnosis, 2021-2030 (US$ Billion)

Table 18 North America Hemangioma Treatment Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 19 North America Hemangioma Treatment Market Value, By End Users, 2021-2030 (US$ Billion)

Table 20 North America Hemangioma Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 South America Hemangioma Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 22 South America Hemangioma Treatment Market Value, By Diagnosis, 2021-2030 (US$ Billion)

Table 23 South America Hemangioma Treatment Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 24 South America Hemangioma Treatment Market Value, By End Users, 2021-2030 (US$ Billion)

Table 25 South America Hemangioma Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 26 Europe Hemangioma Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 27 Europe Hemangioma Treatment Market Value, By Diagnosis, 2021-2030 (US$ Billion)

Table 28 Europe Hemangioma Treatment Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 29 Europe Hemangioma Treatment Market Value, By End Users, 2021-2030 (US$ Billion)

Table 30 Europe Hemangioma Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 31 Asia-Pacific Hemangioma Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 32 Asia-Pacific Hemangioma Treatment Market Value, By Diagnosis, 2021-2030 (US$ Billion)

Table 33 Asia-Pacific Hemangioma Treatment Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 34 Asia-Pacific Hemangioma Treatment Market Value, By End Users, 2021-2030 (US$ Billion)

Table 35 Asia-Pacific Hemangioma Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 36 Middle East & Africa Hemangioma Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 37 Middle East & Africa Hemangioma Treatment Market Value, By Diagnosis, 2021-2030 (US$ Billion)

Table 38 Middle East & Africa Hemangioma Treatment Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 39 Middle East & Africa Hemangioma Treatment Market Value, By End Users, 2021-2030 (US$ Billion)

Table 40 Cutera Inc.: Overview

Table 41 Cutera Inc.: Product Portfolio

Table 42 Cutera Inc.: Key Developments

Table 43 Merck & Co.: Overview

Table 44 Merck & Co.: Product Portfolio

Table 45 Merck & Co.: Key Developments

Table 46 AbbVie Inc: Overview

Table 47 AbbVie Inc: Product Portfolio

Table 48 AbbVie Inc: Key Developments

Table 49 Akorn Pharmaceuticals: Overview

Table 50 Akorn Pharmaceuticals: Product Portfolio

Table 51 Akorn Pharmaceuticals: Key Developments

Table 52 Pfizer Inc.: Overview

Table 53 Pfizer Inc.: Product Portfolio

Table 54 Pfizer Inc.: Key Developments

Table 55 Alma Lasers ltd.: Overview

Table 56 Alma Lasers ltd.: Product Portfolio

Table 57 Alma Lasers ltd.: Key Developments

Table 58 Allergan: Overview

Table 59 Allergan: Product Portfolio

Table 60 Allergan: Key Developments

Table 61 Linline Medical Systems: Overview

Table 62 Linline Medical Systems: Product Portfolio

Table 63 Linline Medical Systems: Key Developments

Table 64 Pierre Fabre : Overview

Table 65 Pierre Fabre : Product Portfolio

Table 66 Pierre Fabre : Key Developments

Table 67 IRIDEX Corporation: Overview

Table 68 IRIDEX Corporation: Product Portfolio

Table 69 IRIDEX Corporation: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Hemangioma Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Hemangioma Treatment Market Share, By Diagnosis, 2022 & 2030 (%)

Figure 4 Global Hemangioma Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 5 Global Hemangioma Treatment Market Share, By End Users, 2022 & 2030 (%)

Figure 6 Global Hemangioma Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Hemangioma Treatment Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 8 Capillary Hemangioma Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 9 Cavernous Hemangioma Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 10 Compund Hemangioma Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 11 Lobular Capillary Hemangioma Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 12 Global Hemangioma Treatment Market Y-o-Y Growth, By Diagnosis, 2022-2030 (%)

Figure 13 Ultrasound Diagnosis in Global Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 14 MRI Diagnosis in Global Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 15 CT Scan Diagnosis in Global Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 16 Others Diagnosis in Global Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 17 Global Hemangioma Treatment Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 18 Medical therapy Treatment in Global Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 19 Laser Therapy Treatment in Global Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 20 Surgery Treatment in Global Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 21 Beta Blocker Medicines Treatment in Global Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 22 Global Hemangioma Treatment Market Y-o-Y Growth, By End Users, 2022-2030 (%)

Figure 23 Hospitals End Users in Global Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 24 Clinics End Users in Global Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 25 Diagnostic Centers End Users in Global Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 26 Others End Users in Global Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 27 Global Hemangioma Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 28 North America Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 29 Asia-Pacific Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 30 Europe Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 31 South America Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 32 Middle East and Africa Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 33 North America Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 34 North America Hemangioma Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 35 North America Hemangioma Treatment Market Share, By Diagnosis, 2022 & 2030 (%)

Figure 36 North America Hemangioma Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 37 North America Hemangioma Treatment Market Share, By End Users, 2022 & 2030 (%)

Figure 38 North America Hemangioma Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 39 South America Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 40 South America Hemangioma Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 41 South America Hemangioma Treatment Market Share, By Diagnosis, 2022 & 2030 (%)

Figure 42 South America Hemangioma Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 43 South America Hemangioma Treatment Market Share, By End Users, 2022 & 2030 (%)

Figure 44 South America Hemangioma Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 45 Europe Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 46 Europe Hemangioma Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 47 Europe Hemangioma Treatment Market Share, By Diagnosis, 2022 & 2030 (%)

Figure 48 Europe Hemangioma Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 49 Europe Hemangioma Treatment Market Share, By End Users, 2022 & 2030 (%)

Figure 50 Europe Hemangioma Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 51 Asia-Pacific Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 52 Asia-Pacific Hemangioma Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 53 Asia-Pacific Hemangioma Treatment Market Share, By Diagnosis, 2022 & 2030 (%)

Figure 54 Asia-Pacific Hemangioma Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 55 Asia-Pacific Hemangioma Treatment Market Share, By End Users, 2022 & 2030 (%)

Figure 56 Asia-Pacific Hemangioma Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 57 Middle East & Africa Hemangioma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 58 Middle East & Africa Hemangioma Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 59 Middle East & Africa Hemangioma Treatment Market Share, By Diagnosis, 2022 & 2030 (%)

Figure 60 Middle East & Africa Hemangioma Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 61 Middle East & Africa Hemangioma Treatment Market Share, By End Users, 2022 & 2030 (%)

Figure 62 Cutera Inc.: Financials

Figure 63 Merck & Co.: Financials

Figure 64 AbbVie Inc: Financials

Figure 65 Akorn Pharmaceuticals: Financials

Figure 66 Pfizer Inc.: Financials

Figure 67 Alma Lasers ltd.: Financials

Figure 68 Allergan: Financials

Figure 69 Linline Medical Systems: Financials

Figure 70 Pierre Fabre : Financials

Figure 71 IRIDEX Corporation: Financials

세계 혈관종 치료 시장 – 2023-2030

Global Hemangioma Treatment Market - 2023-2030